⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

July 4, 2009Expert Opinion on Drug Metabolism & Toxicology

Recent developments in clopidogrel pharmacology and their relation to clinical outcomes

View Full Paper

Ask AI

Bookmark

Share

Design

Review

Authors

PGPaul A. GurbelInterventional Cardiology MAMark J. AntoninoCenter for Devices and Radiological Health UTUdaya S. TantrySinai Hospital

Discussion

Loading...

Member takes

Implication

May support pharmacogenetic testing for clopidogrel nonresponders; leaves open outcome benefits in prospective trials.

Key Points

Key points are not available for this paper at this time.

Cite This Study

Gurbel et al. (2009) studied this question.

synapsesocial.com/papers/69ffcb977e61d2a3f0c23095 https://doi.org/10.1517/17425250903107772

Topics

Dual antiplatelet therapy

View Full Paper

Ask AI

Bookmark

Share

Also Consider

Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context:

1Atorvastatin Reduces the Ability of Clopidogrel to Inhibit Platelet Aggregation2003 · 691 citations
2Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation2008 · 653 citations
3The Relation of Dosing to Clopidogrel Responsiveness and the Incidence of High Post-Treatment Platelet Aggregation in Patients Undergoing Coronary Stenting2005 · 381 citations